Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.

Authors	N Polverelli, L Catani, N Vianelli, M Baccarani, M Cavo, F Palandri
Journal	Annals of hematology (Ann Hematol) Vol. 94 Issue 9 Pg. 1585-7 (Sep 2015) ISSN: 1432-0584 [Electronic] Germany
PMID	25975976 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References	Antisickling Agents Nitriles Pyrazoles Pyrimidines Pyrrolidines Sulfonamides fedratinib ruxolitinib Hydroxyurea
Topics	Antisickling Agents (administration & dosage) Humans Hydroxyurea (administration & dosage) Male Middle Aged Nitriles Platelet Count Pyrazoles (administration & dosage, adverse effects) Pyrimidines Pyrrolidines Splenomegaly (blood, chemically induced, drug therapy) Sulfonamides Thrombocytosis (blood, chemically induced, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!